Novo Nordisk Halts Development Of AERx, Its Phase III Fast-Acting Inhaled Insulin Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly/Alkermes' AIR and MannKind's Technosphere Insulin System still aim for market where Exubera failed.
You may also be interested in...
Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory
Refocused Danish pharma drops its inhaled-insulin portfolio, while swapping last oncologic for an anti-inflammatory.
Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory
Refocused Danish pharma drops its inhaled-insulin portfolio, while swapping last oncologic for an anti-inflammatory.
Inhaled Insulin is Dead. Long Live Inhaled Insulin
In early March, Eli Lilly became the third major pharmaceutical company to scupper its inhaled insulin program. Almost immediately the blogosphere began nailing inhaled insulin's coffin shut. IN VIVO thinks it's still too soon to deliver a eulogy. One company, MannKind, continues undaunted, despite the setbacks for it's competitors, hoping to bring its inhaled insulin to market by 2010. Meantime, specialty pharmaceutical companies or glucose monitoring testing outfits might be interested in the inhaled programs spurned by Big Pharma, but only for the right price.